iTeos Therapeutics - Immunotherapies By Design
Cancer Immunotherapies by Design ™
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients . We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.
introduction
Pipeline
iTeos focuses upon selected key mechanisms by which cancer cells suppress the immune system.
The identification of these mechanisms is based on gene expression profiles of immune cell subsets as they recognize tumor cell targets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of laboratory models.
| Program | Trial Design | Indications | Preclinical | Phase 1 | Phase 1b/2a | Phase 2/3 | |
|---|---|---|---|---|---|---|---|
| Adenosine A2A Receptor Antagonist | |||||||
|
Inupadenant
|
Monotherapy | Solid tumors | |||||
| + pembrolizumab | Anti-PD-1-Resistant Melanoma | ||||||
| + pembrolizumab | Castrate-Resistant Prostate Cancer | ||||||
| + paclitaxel carboplatin | Triple-Negative Breast Cancer | ||||||
| Anti-TIGITmAb FcyR-Engaging | |||||||
|
EOS-448
|
Dose Finding, PK/PD | Solid tumors | |||||
| + IMID | Multiple Myeloma | ||||||
| + pembrolizumab | Solid Tumors | ||||||
| + Inupadenant | Solid Tumors | ||||||
| Preclinical Pipeline | |||||||
|
Adenosine Pathway Inhibitor
|
Oncology | ||||||